Alx Oncology Advances CD47 Biomarker-Driven Strategy, Extends Cash Runway

Alx Oncology reported significant progress in its clinical programs, particularly with evorpacept and ALX2004, and extended its cash runway into Q1 2027. The company's CD47 biomarker-driven strategy and partnered studies, such as the UMBRELLA study with Sanofi, are notable achievements. However, challenges remain in defining biomarker cutoffs and addressing unmet needs in HER2-positive breast cancer.